Abstracts 3294 to 3303 AHA Oral Session, WednesdayHARVEY WHITE, Green Lane Hospital, Auckland Anti-thrombin therapies for patients with acute coronary syndromes were the subject of a session covering such new agents as fondaparinux and bivalirudin, and discussing therapy with heparins, aspirin, clopidogrel and glycoprotein 2b3a inhibitors. Harvey White co-chaired the session and told Peter Goodwin what he thought were some of the key clinical implications emerging.